Ardelyx Inc., of Fremont, Calif., said it licensed to Paris-based Sanofi SA its phosphate transport NaP2b inhibitor program (also known as NaPi2b, Npt2b and SCL34A2) in exchange for an undisclosed up-front payment and total development and regulatory milestones potentially reaching up to $198 million.